BCG026 / Biocytogen - LARVOL DELTA

BCG026: FAP × GPC1 bispecific ADC - A novel targeting approach for stromal and tumor cells in pancreatic cancer and other solid tumors (AACR 2026) - "Furthermore, BCG026 demonstrated potent efficacy in pancreatic and lung cancer PDX models, as well as a superior synergistic effect to that of the parent ADCs in certain models.Conclusion These findings underscore its significant potential as a powerful therapeutic agent for targeting PAAD and other tumors. Further preclinical studies are currently underway."

ADC • Bispecific • Stroma • Tumor cell • Breast Cancer • Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • CAFs • FAP • GPC1